NSPR InspireMD

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany

Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented 

TEL AVIV, Israel, Jan. 27, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc.  (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020 to be held from January 28th to the 31st at the Trade Fair Leipzig, Hall 2 in Leipzig, Germany.  CGuard™ EPS will also be featured in three panel discussions and two scientific posters at the conference.

Live case:

Tuesday, 10:18 – 10:48 Live from Bergamo Technical Forum · Room 3

Case 17 – BG 03: male, 82 years (P-R)

Symptomatic high-risk coronary artery disease

Operators: F. Castriota, A. Micari

Additional presentations featuring CGuard™ EPS will include:

  

What:              Immediate and one-month results from a prospective real-world multicentre clinical practice of CAS using the CGuard embolic prevention system: The IRONGUARD 2 study P. Sirignano

When:              January 28, 12:45 – 12:50 PM Central European Time

Where:            Room 6 – Speaker’s Corner

What:              Accumulating long-term evidence for the MicroNet-covered stent safety, efficacy and durability in primary and secondary stroke prevention: 5-year data from the PARADIGM-Extend prospective academic trial P. Musialek

When:              January 28, 12:50 – 12:55 PM Central European Time

Where:            Room 6 – Speaker’s Corner

What:              OPTIMAI endovascular sequestration of high-risk carotid plaque using the CGuard™ MicroNET-covered embolic prevention stent system in consecutive patients with symptoms or signs of carotid stenosis-related brain injury: An intravascular ultrasound – controlled investigator-initiated multicentric multi-specialty study (CGuard OPTIMA) P. Musialek

When:              January 28, 12:55 – 13:00 PM Central European Time

Where:            Room 6 – Speaker’s Corner

What:              Reconstruction of left subclavian artery using carotid technology B. Huasen

When:              January 28, 14:30 – 14:35 PM Central European Time

Where:            Main Arena 1

What:              The use of CGuard stents; U.K. experience B. Huasen

When:              January 28, 16:35 – 16:40 PM Central European Time

Where:            Main Arena 1

The CGuard™ Carotid Embolic Prevention System will also be featured at the Company’s booth (16d2). InspireMD will be represented by its management, sales and clinical staff and welcomes all enquiries from clinicians and other interested parties.

About LINC

LINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different specialties around the world who perform endovascular interventions.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

888-776-6804

Email:   

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

Email: 

EN
27/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InspireMD

 PRESS RELEASE

InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinic...

InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure TEL AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that early results from the investigator-initiated SIBERIA randomized clinical t...

 PRESS RELEASE

InspireMD Announces Publication of 12-Month Results of CGuardâ„¢ EPS P...

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that 12-month PARADIGM trial results have been published in the EuroIntervention jour...

 PRESS RELEASE

InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Optio...

InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 million follow-on underwritten public offering, which included $1.5 million from the exercise, in full, by the underwriter of its over-allotment option for the offering. Pur...

 PRESS RELEASE

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public O...

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of $0.45 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $10.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional...

 PRESS RELEASE

InspireMD Announces First Quarter 2020 Financial Results

InspireMD Announces First Quarter 2020 Financial Results First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today, May 12, at 8:30am ET TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the first quarter ended Ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch